Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.

[1]  T. Bjørge,et al.  Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993 , 1998, International journal of cancer.

[2]  C. Tropé,et al.  Current status of chemotherapy in gynecologic cancer. , 1997, Seminars in oncology.

[3]  C. Tropé,et al.  Tamoxifen in the Treatment of Recurrent Ovarian Carcinoma , 1997 .

[4]  R. Ozols.  Treatment of recurrent ovarian cancer: increasing options--"recurrent" results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A Gordon,et al.  Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Meden,et al.  Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum. , 1997, European journal of cancer.

[7]  M. Piver,et al.  Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. , 1996, Gynecologic oncology.

[8]  K. Hatch,et al.  Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. , 1996, Gynecologic oncology.

[9]  H. Earl,et al.  Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. , 1995, British Journal of Cancer.

[10]  J B Vermorken,et al.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Groshen,et al.  Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Thigpen,et al.  Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Cain,et al.  Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. , 1994, American journal of obstetrics and gynecology.

[14]  J. Ferlay,et al.  Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden , 1993, International journal of cancer.

[15]  M. Christian,et al.  Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. C. Dubbelman,et al.  Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  I. Vergote,et al.  Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. , 1992 .

[18]  C. Runowicz,et al.  Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Coebergh,et al.  Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study. , 1991, Gynecologic oncology.

[20]  S. Rubin,et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Gore,et al.  Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. , 1990, Gynecologic oncology.

[22]  D. Ettinger,et al.  Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. , 1989 .

[23]  C. Redman,et al.  Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. , 1989, British Journal of Cancer.

[24]  J. Haybittle,et al.  Long-term survival experience of female patients with genital cancer. , 1988, British Journal of Cancer.

[25]  M. Piver.  Ovarian carcinoma: A decade of progress , 1984, Cancer.

[26]  G. Fountzilas,et al.  A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study. , 1997, European Journal of Cancer.

[27]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .